MorphoSys AG

MorphoSys and Celgene Mutually Agree to End MOR202 Collaboration - Seite 2

2015 Guidance Update:

As a result of the termination of the co-development and co-promotion agreement for MOR202, MorphoSys has updated its financial guidance. The Company now expects revenues for the 2015 financial year in the amount of EUR 101 million to EUR 106 million (up from previously EUR 58 million to EUR 63 million) due to the full realization of deferred revenues from the original agreement with Celgene and a one-time payment from Celgene for development costs in 2015. Based on management's current planning, proprietary R&D expenses are expected to increase to a range of EUR 56 million to EUR 63 million (previously EUR 48 million to EUR 58 million), including the development costs for MOR202 for the remainder of the year. The Company now expects earnings before interest and taxes (EBIT) of approximately EUR 9 million to EUR 16 million in 2015 (previously EUR -20 million to EUR -30 million).

MorphoSys will hold a conference call on Friday, March 27, 2015, to discuss this announcement.

Dial-in number for the analyst conference call (in English) at 01:00 pm CET; 12:00 pm GMT; 08:00 am EST (listen-only):

Germany:                               [phone]

For UK residents:                   [phone]

For US residents:                   [phone]

Please dial in 10 minutes before the beginning of the conference.

The replay and transcript will be made available at http://www.morphosys.com.

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 90 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.